3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
11
Lymphoma, Non-Hodgkin
9
Lymphoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myeloid, Acute
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hodgkin Disease
5
Myelodysplastic Syndromes
4
Neoplasms, Plasma Cell
3
Melanoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
3
Glioma
3
Primary Myelofibrosis
2
Myeloproliferative Disorders
2
Lymphoma, B-Cell
2
Immunoglobulin Light-chain Amyloidosis
2
Hematologic Neoplasms
2
Glioblastoma
2
Carcinoma, Non-Small-Cell Lung
2
Burkitt Lymphoma
2
Wilms Tumor
1
Sarcoma
1
Recurrence
1
Philadelphia Chromosome
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Interventions
Carboplatin
158
Paclitaxel
152
Bevacizumab
85
Gemcitabine
48
liposomal doxorubicin
47
Taxes
47
Topotecan
41
Cisplatin
34
pembrolizumab
33
Cyclophosphamide
28
olaparib
25
Immunoglobulin G
24
Disulfides
24
Specimen Handling
20
Docetaxel
20
Drug Therapy
19
Magnetic Resonance Spectroscopy
17
niraparib
16
Doxorubicin
16
Biopsy
15
mirvetuximab soravtansine
14
Hyperthermic Intraperitoneal Chemotherapy
13
rucaparib
12
Nivolumab
12
Cytoreduction Surgical Procedures
10
Albumin-Bound Paclitaxel
10
veliparib
9
Platinum
9
Chemotherapy, Adjuvant
9
130-nm albumin-bound paclitaxel
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Fallopian Tube Neoplasms
×
Blood Component Removal
×
Clear all
NCT05920798
2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2
Recruiting
40 enrolled